While pre-clinical research has shown that the combination of apoCIII ASO and cholesterol lowering halts plaque development, says Dr Philip Gordts, further research is needed to fully understand the effects of apoCIII inhibition alone on plaque progression in established lesions and any potentially adverse effects on smooth muscle cells.